Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Achillion Pharmaceuticals, Inc.    ACHN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Achillion Shares Slide On Results From Hepatitis C Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/23/2012 | 04:57pm CET

Achillion Pharmaceuticals Inc.'s (>> Achillion Pharmaceuticals, Inc.) shares declined Monday as Phase II study data for its lead hepatitis C treatment was deemed disappointing in light of the recent success of peers.

Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.), Gilead Sciences Inc. (>> Gilead Sciences, Inc.) and others, including Abbott Laboratories (>> Abbott Laboratories), are racing to bring an all-oral hepatitis C regimen to market, hoping to tap what is expected to be a multibillion-dollar market for such a therapy. Gilead shares surged last week as it appeared to be leading the race: it hopes to bring a GS-7977-based therapy to market late next year or in 2014.

Achillion shares were down 12% at $7.25 in recent trading, pushing their decline for the past three months to 21%.

Over the weekend, Achillion presented final results of a 12-week study of its ACH-1625 treatment in combination with standard-of-care treatment at a European Association for the Study of the Liver conference in Barcelona, along with plans to combine a study of the oral drug candidate with another treatment later this year.

The company on Saturday had reported that in the second segment of its Phase 2a trial of ACH-1625, 94% to 100% of patients achieved a complete early virologic response after 12 weeks of the experimental treatment in combination with pegylated interferon alfa-2a and ribavirin. The company also reported the combined treatments were safe and well tolerated and produced high viral response rates.

J.P. Morgan Chase & Co. (JPM) said in a research note the data Achillion presented on Saturday "raises eyebrows" as it downgraded the stock to market perform from market outperform.

"Overall, the data were confusing and raised questions regarding the interim safety and efficacy analysis, particularly regarding the compounds ability to clear the virus relative to other competitive agents, liver elevations, and gastrointestinal symptoms," the analysts said. "As such, we are waiting on the sidelines until we get a better handle on the breadth of the therapeutic window."

Achillion on Monday aimed to clarify data regarding end-of-treatment data included in the data presented over the weekend.

The company in a statement said that 58 patients were given a once-daily dose of 200 milligrams, 400 milligrams or 800 milligrams of ACH-1625 pegylated interferon and ribavirin for 12 weeks. At the time of the presentation, 22 of the patients had completed 12 weeks of ACH-1625 plus the other two drugs followed by 12 weeks of pegylated interferon and ribavirin. At the end of 24 weeks all 22 patients had undetectable levels of the virus.

"We are providing these results as we recognized that some of the data was not clear" during its presentation at the conference, Achillion President and Chief Executive Michael Kishbauch said.

Oppenheimer analysts said earlier Monday that based on the results, "we believe '1625 has meaningful strategic value and could play a role in an all-oral combination regimen."

However, the analysts also said that despite their favorable view of 1625 and Achillion's earlier hepatitis C pipeline they believe the stock currently "reflects appropriate value for these programs."

The study data was released a few days after another study found a regimen combining experimental drugs from Gilead and Bristol-Myers suppressed the hepatitis C virus in most patients four weeks after completing treatment. In a separate study, Gilead also said a combination of its drug, GS-7977, with an older drug, ribavirin, suppressed the liver-disease-causing virus in most patients four weeks after treatment.

The results bolster the prospects for an all-oral regimen for hepatitis C that eliminates an injectable drug used in the current standard treatment, interferon, which can be difficult for patients to tolerate.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACHILLION PHARMACEUTICALS,
02/23 ACHILLION PHARMACEUTICALS : reports 4Q loss
02/23 ACHILLION PHARMACEUTICALS, INC. (NAS : ACHN) Files An 8-K Results of Operations ..
02/23 ACHILLION PHARMACEUTICALS INC : Results of Operations and Financial Condition, F..
02/23 ACHILLION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
02/23 Achillion Reports 2016 Fourth Quarter and Year-End Financial Results
02/22 ACHILLION PHARMACEUTICALS, INC. : Biotech's Rally Continues to Build in 2017: To..
02/13 Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Con..
01/11 WEDNESDAY SECTOR LAGGARDS : Drugs, Biotechnology Stocks
2016 ACHILLION PHARMACEUTICALS : Announces Clinical Milestone for the Advancement of ..
2016 ACHILLION PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Fina..
More news
Sector news : Bio Therapeutic Drugs
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02/24 Achillion down 5% after Q4 results
02/23 Achillion -5% after earnings, outlook, share sale plans
02/23 Achillion Pharmaceuticals beats by $0.15
02/22 Notable earnings after Thursday?s close
02/02 Premarket analyst action - healthcare
Advertisement
Financials ($)
Sales 2017 30,7 M
EBIT 2017 -52,9 M
Net income 2017 -65,4 M
Debt 2017 0,82 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 17,2x
EV / Sales 2018 5,65x
Capitalization 528 M
More Financials
Chart ACHILLION PHARMACEUTICALS,
Duration : Period :
Achillion Pharmaceuticals, Technical Analysis Chart | ACHN | US00448Q2012 | 4-Traders
Full-screen chart
Technical analysis trends ACHILLION PHARMAC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 8,77 $
Spread / Average Target 127%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Milind S. Deshpande President, Chief Executive Officer & Director
David I. Scheer Chairman
Mary Kay Fenton CFO, Executive VP & Investor Relations Contact
David Apelian Chief Medical Officer & Executive Vice President
Joel C. Barrish Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACHILLION PHARMACEUTIC..-6.54%528
AMGEN, INC.19.39%128 555
GILEAD SCIENCES, INC.-2.33%92 143
CELGENE CORPORATION2.14%91 979
REGENERON PHARMACEUTIC..-1.66%38 296
ACTELION LTD22.36%28 792
More Results